$5.66
4.71% today
Nasdaq, Apr 03, 06:22 pm CET
ISIN
CA31447P1009
Symbol
FENC
Sector
Industry

Fennec Pharmaceuticals Inc. Stock price

$5.94
-0.83 12.26% 1M
+1.32 28.57% 6M
-0.38 6.01% YTD
-5.05 45.95% 1Y
+0.04 0.68% 3Y
+0.51 9.39% 5Y
+3.37 131.13% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.41 7.41%
ISIN
CA31447P1009
Symbol
FENC
Sector
Industry

Key metrics

Market capitalization $163.91m
Enterprise Value $155.35m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 5.88
EV/Sales (TTM) EV/Sales 3.27
P/S ratio (TTM) P/S ratio 3.45
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 123.69%
Revenue (TTM) Revenue $47.54m
EBIT (operating result TTM) EBIT $2.57m
Free Cash Flow (TTM) Free Cash Flow $26.43m
Cash position $26.63m
EPS (TTM) EPS $-0.06
P/E forward 90.00
P/S forward 3.48
EV/Sales forward 3.30
Short interest 7.70%
Show more

Is Fennec Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Fennec Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Fennec Pharmaceuticals Inc. forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Fennec Pharmaceuticals Inc. forecast:

Buy
100%

Financial data from Fennec Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
48 48
124% 124%
100%
- Direct Costs 3.18 3.18
152% 152%
7%
44 44
122% 122%
93%
- Selling and Administrative Expenses 41 41
27% 27%
87%
- Research and Development Expense 0.31 0.31
417% 417%
1%
2.57 2.57
120% 120%
5%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 2.57 2.57
120% 120%
5%
Net Profit -0.07 -0.07
100% 100%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Fennec Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fennec Pharmaceuticals Inc. Stock News

Neutral
Seeking Alpha
24 days ago
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q4 2024 Earnings Conference Call March 10, 2025 8:30 AM ET Company Participants Robert Andrade - CFO Jeff Hackman - CEO and Board Member Conference Call Participants Chase Knickerbocker - Craig-Hallum Raghuram Selvaraju - H.C. Wainwright Felix Ampomah - Stephens Michael Okunewitch - Maxim Group Operator Good morning, ladies and gentlemen, and welcome t...
Neutral
GlobeNewsWire
24 days ago
~ Achieved Full-Year PEDMARK ®  Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK ® Q4 2024 Net Product Sales of $7.9 Million ~
Neutral
GlobeNewsWire
28 days ago
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2024 financial results before the opening of the U.S. financial markets on Monday, March 10, 2025. Management will host a conference call and webc...
More Fennec Pharmaceuticals Inc. News

Company Profile

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Head office Canada
CEO Jeffrey Hackman
Employees 32
Founded 1996
Website www.fennecpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today